...2012 (see BioCentury, Dec. 3, 2012). Leo gained the product through its 2009 acquisition of Peplin Inc....

...year (see BioCentury, Dec. 3, 2012). Leo gained the product through its 2009 acquisition of Peplin Inc....

...year (see BioCentury, Dec. 3, 2012). Leo gained the product through its 2009 acquisition of Peplin Inc....

...Universitaetsmedizin Berlin (see BioCentury, Oct. 8). Leo gained the product through its 2009 acquisition of Peplin Inc....

...Bioscience Fund I include dermatology company Peplin Inc. and autoimmune and cancer play Arana Therapeutics Ltd. Peplin...

...in January (see BioCentury, Jan. 30). Leo gained the product through its 2009 acquisition of Peplin Inc....

...is an ingenol 3-angeloyl topical formulation. Leo gained the product through its 2009 acquisition of Peplin Inc....

...Inc. CEO Thomas Wiggans and CMO Eugene Bauer were both involved with Connetics Corp. and Peplin Inc....
...five dermatology products to market (see BioCentury, Oct. 30, 2006) . The pair reconnected at Peplin...

...Peplin Inc. and former CEO of Connetics Corp. The CMO is Eugene Bauer, formerly CMO of Peplin...

...PEP005 has been submitted for FDA review. Leo gained PEP005 through its 2009 acquisition of Peplin Inc....